Revolution Medicines, Inc. - RVMD Operating profit EBITDA
Revolution Medicines (RVMD) prospects rely on the success of RAS oncology therapy and a stable roster of R&D experts. The estimated EBITDA visualizes the business's cash returns, where the 0.00 mark characterizes this parameter. Future growth is tied to the approval of lung cancer drugs. Development transparency and the management's scientific approach enable the efficient attraction of capital even during the pre-revenue stage.
Revolution Medicines, Inc. (RVMD) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Revolution Medicines|RVMD - Long-Term Debt to Capital|Current Liabilities to Capital Revolution Medicines Inc|RVMD - Company Total Debt|Debt to Book Capitalization Ratio Revolution Medicines|RVMD - Company Long-Term Debt|Short-Term Debt Revolution Medicines|Quick Liquidity revmed.com
- earnings and market ratios statistics:
RVMD - Net Income|Projected Future Earnings Revolution Medicines|RVMD - Price to Earnings Ratio|Market Cap to Future Earnings Ratio revmed.com|RVMD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Revolution Medicines|RVMD - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Revolution Medicines|RVMD - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months revmed.com|RVMD - Net earnings per share growth this year|Expected earnings per share trend next year Revolution Medicines
- sales revenue and business income indicators:
Fundamental company valuation:Revolution Medicines Corp (RVMD)
Operating profit dynamics allow for an assessment of Revolution Medicines (RVMD) financial resilience to inflationary pressure and borrowing costs. Given the colossal expenditures on developing RAS mutation inhibitors, the EBITDA_Co level on this chart reflects the efficiency of cash flow management before taxes and interest. It is critical for investors to monitor this indicator to promptly detect risks of margin erosion and a potential contraction in market capitalization.
Competitors of Revolution Medicines (RVMD)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|AAPG - Operating profit EBITDA|CG Oncology (CGON) - Profit before payment of interest, taxes and amortization|UroGen Pharma Ltd - Income before deduction of interest, taxes and amortization|BCAX (Bicara Bio) - Operating profit EBITDA|Profit before interest, taxes and amortization Personalis Genomics PSNL|Profit before payment of interest, taxes and amortization Erasca, Inc. (ERAS)|DCTH (delcath.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Profit before interest, taxes and amortization|CADL: Operating profit before deduction of amortization|ARAY: Profit before payment of interest, taxes and amortization|sellaslifesciences.com (SLS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization actuatetherapeutics.com (ACTU)|Profit before payment of interest, taxes and amortization Citius Oncology|Profit before payment of interest, taxes and amortization HURA|Operating profit before deduction of amortization TARA (Protara)|Operating profit EBITDA Fate Pharma (FATE)|Aadi Bioscience - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Operating profit EBITDA|Operating income before deduction of amortization XBiotech Inc. XBIT|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization OS Therapies, Inc. (OSTX)|Profit before payment of interest, taxes and amortization Radiopharm Theranostics|Operating profit before amortization ARTV (Artiva)|Operating profit before deduction of amortization ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Tx TPST|XLO - Operating profit before deduction of amortization|Enochian BioSciences - Operating profit EBITDA|Profit before interest, taxes and amortization Mural Oncology plc|KAPA: Operating profit EBITDA|Operating profit before amortization OKUR|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Curis Corp (CRIS) - Operating income before deduction of amortization|Operating profit EBITDA APLM|Operating profit before deduction of amortization tharimmune.com THAR|Operating profit EBITDA ADVB (Advanced Biomed)|Operating income before deduction of amortization Genprex Inc. (GNPX)|CLDI - Profit before payment of interest, taxes and amortization|SBFM (sunshinebiopharma.com) - Operating profit before amortization|XBIO: Operating profit EBITDA|Profit before interest, taxes and amortization salariuspharma.com (SLRX)|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AON (AONC) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Elevation Oncology - Operating profit before deduction of amortization|iCAD Inc. - Profit before payment of interest, taxes and amortization|IKNA - Profit before payment of interest, taxes and amortization|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|Operating profit before amortization MOR|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
